Pyramid Announces Appointment of Amy Driver as Business Development Leader and Peter Buzy to the Board of Directors
12 Sep 2023
Executive Change
Addition of accomplished industry veterans to leadership team and Board poises the company for continued accelerated growth.
COSTA MESA, Calif.--(BUSINESS WIRE)-- Pyramid, a leading large molecule drug product contract development and manufacturing organization (“CDMO”), announced the appointment of Amy Driver as Vice President of Business Development and Peter Buzy to the Board of Directors.
“We are excited to have Amy and Pete join the Pyramid leadership team and the Pyramid Board, respectively, as we continue to invest in our team and resources to support our next phase of growth,” commented Medhat Gorgy, Chief Executive Officer at Pyramid. “Amy’s proven ability to provide excellent service to her clients and industry expertise will help us advance our company’s expansion efforts. Pete’s operational and leadership expertise in the therapeutics industry, and his 30-plus year management track record will help guide our company’s strategic direction as we continue on our trajectory.”
Driver joins Pyramid from Bionova Scientific, where she led the company’s business development efforts. She earned her MBA from USC’s Marshall School of Business, her MS in Toxicology from University of North Carolina, Chapel Hill, and her BS in Chemistry and Biochemistry from the College of Charleston.
“I am excited to join Pyramid at a key inflection point in the company’s growth story and look forward to supporting Pyramid and our clients as a part of the leadership team,” commented Amy Driver, Vice President of Business Development at Pyramid. “Pyramid’s reputation as a leader in the CDMO space and for providing best-in-class quality and service to its clients attracted me to the opportunity. I’m eager to partner with Medhat and the broader Pyramid organization to build on the company’s strong momentum.”
Buzy joins the Board of Directors as an accomplished industry executive, having previously served as President and CEO of Paragon Bioservices leading it to a successful sale to Catalent in 2019. Following the sale of Paragon, he served as the Chairman of Catalent’s Gene Therapy Division until 2021. He also currently serves on the boards of AeroSafe Global, Deka Biosciences, and LumaCyte, and is an Advisory Partner at NewSpring Healthcare.
“Pyramid’s investments in its clients, facilities, employees, and leadership team positions the company well for continued growth alongside its current and new clients,” said Buzy. “The company has an impressive track record for quality and service, and I look forward to partnering with Medhat, the Pyramid team, Audax, and the rest of the Board to navigate this next stage of growth.”
The appointments follow the recent investment in Pyramid by Audax Private Equity, announced in April of this year.
ABOUT PYRAMID LABORATORIES
Pyramid Laboratories, Inc. (“Pyramid Labs” or “Pyramid”) is a California-based CDMO focused on formulation development, analytical and stability testing, and aseptic fill-finish manufacturing focused on large molecule therapeutics. Founded in 1988 by CEO Medhat Gorgy and headquartered in Costa Mesa, California, Pyramid operates three leading-edge manufacturing facilities that allow the Company to offer its pharmaceutical and biotech customers a wide range of services, ranging from preclinical development to scale up aseptic fill-finish commercial manufacturing and distribution. Learn more at PyramidLabs.com or via email at info@pyramidlabs.com.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.